Fz002
Phase 1
Fz002 is one of 9 therapeutic programs targeting Clostridium Difficile Infection. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Clostridium Difficile Infection
#DrugCompanyPhaseTrials
1Dificlir
Merck & Co.Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
ZINPLAVA
Merck & Co.Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Fz002
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
Whole Blood
VVersailles Hospital
Preclinical
Serum
VVersailles Hospital
Preclinical
Stools
VVersailles Hospital
Preclinical
Vancomycin or Fidaxomicin
SSejtterapia Kozpont Kft.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Fz002. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]